金吾财讯 | 招银国际发研指,翰森制药(03692)与默沙东(MSD)共同宣布,双方已签署关于其在研的口服小分子GLP-1受体激动剂HS-10535的全球独家许可协议。根据协议,集团将获得1.12亿美元的预付款,此外还有高达19亿美元的潜在里程碑付款,以及未来的销售提成。在特定条件下,集团可能会在大中华区共同推广或独家商业化HS-10535。默克将评估HS-10535的潜力,特别是其在减重之外,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.